Beyond The Printed Page

  1. What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    While attending BIO’s 2017 annual meeting in San Diego this past June, I had the opportunity to conduct an in-person interview with David Hung, the CEO of Axovant Sciences. In 2016, the former founder of Medivation navigated the successful acquisition of his company by Pfizer for $14.3 billion. Though many might credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, I would argue that there are a number of other predictors that should be evaluated when anticipating future success.

  2. Allergan’s Brent Saunders Shares A Social Contract Secret

    Don't miss this free (all-access) sneak peek of our upcoming September feature article on how Brent Saunders built Allergan’s social contract, a document that may likely define his biopharma legacy. “Over time, as people evaluate my leadership in the role, I hope it is not limited to the social contract," he says.

  3. Coming In September: The Inside Story Of How Allergan Built Its Social Contract

    In the September issue of Life Science Leader, we will feature an article on how Allergan’s Chairman, President, and CEO, Brent Saunders, conceived and created Allergan’s now-famous social contract. You’ll likely be stunned at the approach that was taken.

  4. MMD’s Next Generation Of Leaders

    According to Sanat Chattopadhyay, president of the Merck Manufacturing Division (MMD) and subject of Life Science Leader’s August 2017 feature article, female leaders are going to shape the world in the future.

  5. Successful Transformations Require A Post-Period Of Reflection

    While it is a little early in the Merck Manufacturing Division (MMD) transformation to determine what, if anything, he would have done differently, it is likely Sanat Chattopadhyay will explore this exercise in the near future.

  6. What Would 6 Industry Icons Do Differently If Given The Chance To Be CEO Again?

    When talking with six former pharma CEOs for our Balancing Biopharma’s Bright Future Against Its Tarnished Image — 6 Retired CEOs Share Insights For Today’s Industry Leaders article, we gathered too many great insights to be included within all the pages of a print publication. So, we present that extra content to you here.

  7. Why Would Human Health Companies Want To Partner With Zoetis?

    Scott Brown, D.V.M., Ph.D., VP of external innovation at Zoetis (see our June 2017 feature,) elaborates on some of the challenges faced by the animal health company post IPO in creating research collaborations, as well as why human-health oriented companies might want to consider collaborating with an animal–health-focused company like Zoetis.

  8. IO KOLs Speak On

    More thoughts and comments from cancer immunotherapy experts augment our 2017 immuno-oncology update.

  9. 6 Industry Icons Weigh In On Internal Rate Of Return For Biopharma R&D

    In the July 2017, Life Science Leader magazine we will be publishing the article — Balancing Biopharma’s Bright Future Against Its Tarnished Image — 6 Retired CEOs Share Insights For Today’s Industry Leaders. The story features six former CEOs: Mike Bonney (Cubist); Hank McKinnell, Ph.D., (Pfizer); Francois Nader, M.D., (NPS Pharmaceuticals); David Pyott (Allergan); Stephen Sherwin, M.D., (Cell Genesys); and Henri Termeer (Genzyme).

  10. CSL Limited CEO Shares Insights Beyond Just How To Grow Revenue

    Being the head of any Big Pharma is bound to test an executive’s work-life balance. But when that Big Pharma is headquartered in Australia, and the company prides itself on being a “global operation,” maintaining any kind of work-life balance is a formidable task. “I’m not the poster child for how to strive for work-life balance,” admits Paul Perreault, CEO and managing director of CSL.